Second Analysis of FLAURA2 Trial Extends Benefit of Osimertinib Combo in NSCLC
Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.
Physician Practices, Healthcare Organizations See Own Staff as Source of Security Breaches
Fine Print of Budget Deal Doesn't Bode Well for SGR Overhaul
